Wide Ranks

ERAS

Erasca, Inc.

2.92

Top Statistics
Market Cap 825 M Forward PE -4.69 Revenue Growth 0.00 %
Current Ratio 0.00 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -3.12 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 408 M Total Cash Per Share 1.45 Total Debt 53 M
Total Debt To Equity 11.96 Current Ratio 0.00 Book Value Per Share 1.65
All Measures
Short Ratio 1992.00 % Message Board Id finmb_595471999 Shares Short Prior Month 33 M
City San Diego Uuid 3eb26e05-0e9c-3836-891c-6af153666702 Previous Close 2.78
First Trade Date Epoch Utc 1 B Book Value 1.65 Beta 1.16
Total Debt 53 M Volume 1 M Price To Book 1.77
Fifty Two Week Low 1.51 Total Cash Per Share 1.45 Shares Short Previous Month Date 1 B
Target Median Price 5.50 Max Age 86400 Recommendation Mean 1.67
Sand P52 Week Change 0.3133 Target Mean Price 5.75 Net Income To Common -159119008
Short Percent Of Float 0.1292 Implied Shares Outstanding 282 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M Average Volume10days 1 M
Total Cash 408 M Next Fiscal Year End 1 B Held Percent Insiders 0.1239
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 2.78 Target Low Price 3.50 Gmt Off Set Milliseconds -18000000
Fifty Day Average 2.74 Open 2.85 Dividend Yield 0.00 %
State CA Time Zone Short Name EST Trailing Eps -0.7900
Day Low 2.79 Address1 3115 Merryfield Row Shares Outstanding 282 M
Price Hint 4 Target High Price 11.00 Website https://www.erasca.com
52 Week Change 0.7176 Average Volume 1 M Forward Eps -0.7400
Recommendation Key buy Compensation As Of Epoch Date 1 B Is_sp_500 False
Regular Market Day High 2.93 Profit Margins 0.00 % Debt To Equity 11.96
Fifty Two Week High 3.45 Day High 2.93 Shares Short 32 M
Regular Market Open 2.85 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.1137 Currency USD
Time Zone Full Name America/New_York Market Cap 825 M Is_nasdaq_100 False
Zip 92121 Quote Type EQUITY Industry Biotechnology
Long Name Erasca, Inc. Regular Market Day Low 2.79 Held Percent Institutions 0.8700
Current Price 2.92 Address2 Suite 300 Enterprise To Ebitda -3.12
Financial Currency USD Current Ratio 0.00 Industry Disp Biotechnology
Number Of Analyst Opinions 8 Country United States Float Shares 215 M
Two Hundred Day Average 2.49 Enterprise Value 470 M Forward PE -4.69
Regular Market Volume 1 M Ebitda -150906000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma.

It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors.

In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme.

The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds.

Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.